Integra LifeSciences (NASDAQ:IART) Shares Up 6.2% After Analyst Upgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares traded up 6.2% during trading on Thursday after Truist Financial raised their price target on the stock from $14.00 to $19.00. Truist Financial currently has a hold rating on the stock. Integra LifeSciences traded as high as $20.00 and last traded at $19.9350. Approximately 97,377 shares were traded during mid-day trading, a decline of 89% from the average session volume of 888,973 shares. The stock had previously closed at $18.78.

Several other equities analysts have also issued reports on the company. Citigroup restated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. BMO Capital Markets initiated coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Thursday, June 18th. Finally, Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Reduce” and an average price target of $18.33.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $4,722,000. Hsbc Holdings PLC purchased a new stake in Integra LifeSciences in the fourth quarter worth $879,000. Tejara Capital Ltd lifted its stake in Integra LifeSciences by 42.6% in the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after acquiring an additional 51,300 shares during the period. Assenagon Asset Management S.A. lifted its stake in Integra LifeSciences by 15.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock worth $6,537,000 after acquiring an additional 71,950 shares during the period. Finally, Systematic Financial Management LP boosted its holdings in Integra LifeSciences by 4.5% in the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after acquiring an additional 48,094 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 5.7%

The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. The stock’s 50-day simple moving average is $16.81 and its 200-day simple moving average is $13.04. The firm has a market capitalization of $1.54 billion, a PE ratio of -3.07, a P/E/G ratio of 1.30 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13. The business had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.